Country for PR: Australia
Contributor: AAP Medianet International
Thursday, May 28 2020 - 17:18
AsiaNet
Seaweed Extract Offers Hope for Influenza A
CAMBRIDGE, Australia, May 28, 2020/Medianet International-AsiaNet/--

Australian scientists have revealed that a natural compound found in seaweed 
may reduce the effects of severe cases of Influenza A.

Fucoidan is a highly bioactive compound found naturally in brown seaweed and 
well known for its diverse therapeutic potential. Amongst other benefits, 
fucoidan is known for its effects on modulating inflammation and inhibiting 
certain viruses. 

The new research involved studying the effect of fucoidan in mice that had been 
infected with Influenza A H1N1. The results demonstrated that mice that had 
consumed the fucoidan experienced a significant reduction in lung 
'consolidation' - a common adverse effect of severe viral lung infections in 
which fluid fills the alveoli of the lungs and interferes with vital gas 
exchange. Recovery from this condition can be lengthy and may include permanent 
damage to lung tissue. 

The study also showed that oral consumption of fucoidan resulted in a reduction 
in the clinical signs of Influenza A. 

The fucoidan utilised in the study was Maritech(R) Undaria pinnatifida fucoidan 
manufactured by Australian biotechnology company Marinova Pty Ltd. Maritech(R) 
seaweed extracts are supplied directly to leading pharmaceutical and 
nutritional companies for inclusion in a range of human health applications. 

Speaking about the results, co-author of the paper and Chief Scientist at 
Marinova Pty Ltd, Dr Helen Fitton, said, "These results are very exciting. They 
demonstrate the potential for fucoidan to be utilised as a natural therapy for 
the management of viral infections where lung damage is occurring."

The full paper, 'Oral fucoidan attenuates lung pathology and clinical signs in 
a severe Influenza A mouse model', published in Marine Drugs, can be accessed 
here[https://www.mdpi.com/1660-3397/18/5/246].

About Marinova 
Marinova is a progressive Australian biotechnology company dedicated to the 
development of high purity seaweed extracts for the betterment of human health. 
The company specialises in the research, development and manufacture of 
fucoidan compounds for use in nutritional, pharmaceutical and dermatological 
applications. 


SOURCE: Marinova Pty Ltd